In 2025, Chugai Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Chugai Pharmaceutical has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 49,175a | 50,406a | 47,991b | |
Total Scope 2 | ||||
Market-Based | 1,167a | 3,267b | 3,458b | |
Location-Based | N/A | 65,695b | 64,663b | |
Total Scope 3 | 1,103,831a | 980,000a | 1,141,000a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 6.1221a | 6.7601a | 6.1072b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Chugai Pharmaceutical amounted to 50,342 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Chugai Pharmaceutical decreased by 56.64%, showing that the company has made progress in taking action to reduce the climate impact of its operations.ab
In 2025, the total Scope 1 emissions of Chugai Pharmaceutical were 49,175 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Chugai Pharmaceutical's Scope 1 emissions have increased by 2.26%, reflecting a rising long-term trend in Scope 1 emissions over time.ac
Compared to the previous year (2024), Chugai Pharmaceutical's Scope 1 emissions decreased by 2.44%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2025, Chugai Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 1,167 tCO₂e using the market-based method.a
In 2025, Chugai Pharmaceutical reported its Scope 2 emissions using the market-based method.a
In 2025, Chugai Pharmaceutical reported 1,103,831 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Chugai Pharmaceutical includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, up from 3 in 2024, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
In 2025, Chugai Pharmaceutical reported total Scope 3 emissions of 1,103,831 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 99.99% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.01% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2019, Chugai Pharmaceutical's Scope 3 emissions have increased by 14.15%, reflecting a rising long-term trend in Scope 3 emissions over time.a
Compared to the previous year (2024), Chugai Pharmaceutical's Scope 3 emissions increased by 12.64%, suggesting that the company faced challenges in reducing emissions across its value chain.a
In 2025, Chugai Pharmaceutical reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2025, the largest contributors to Chugai Pharmaceutical's Scope 3 emissions were:a
In 2025, Chugai Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 49,175 tCO₂e and total revenues of USD 8,032 millions. This translates into an emissions intensity of 6.12 tCO₂e per millions USD.a
In 2025, Chugai Pharmaceutical reported a Scope 1 emissions intensity of 6.12 tCO₂e per millions USD. Compared to the peer group median of 5.07, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2025, Chugai Pharmaceutical ranked 16 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Chugai Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2025, Chugai Pharmaceutical reported a total carbon footprint of 1,154,173 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 5.3% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.ab
The largest contributor to Chugai Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 95.64% of the company's total carbon footprint, followed by Scope 1 emissions at 4.26%.a